DNTH vs. TXG
DNTH (Dianthus Therapeutics Inc.) and TXG (10x Genomics, Inc.) are both stocks. Both are in the Healthcare sector — DNTH in Biotechnology, TXG in Health Information Services. Over the past year, DNTH returned 419.28% vs 261.39% for TXG. Their 0.24 correlation means their historical movements had little consistent relationship.
Performance
DNTH vs. TXG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DNTH achieves a 159.45% return, which is significantly lower than TXG's 189.82% return.
DNTH
- 1D
- -5.08%
- 1M
- 13.33%
- 6M
- 100.26%
- YTD
- 159.45%
- 1Y
- 419.28%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 124.41%
TXG
- 1D
- -4.37%
- 1M
- 21.17%
- 6M
- 134.01%
- YTD
- 189.82%
- 1Y
- 261.39%
- 3Y*
- -8.77%
- 5Y*
- -23.74%
- 10Y*
- —
- ALL TIME*
- -1.92%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $89.59M | $95.14M | $92.66M | |
| $119.53M | $127.35M | $106.42M |
DNTH vs. TXG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
DNTH Dianthus Therapeutics Inc. | 159.45% | 89.04% | 109.62% | 0.00% |
TXG 10x Genomics, Inc. | 189.82% | 13.58% | -74.34% | 16.58% |
Correlation
The correlation between DNTH and TXG is 0.25, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.25 |
Correlation (All Time) Calculated using the full available price history since Sep 12, 2023 | 0.24 |
Fundamentals
DNTH:
$4.46B
TXG:
$6.00B
DNTH:
-$0.45
TXG:
-$0.18
DNTH:
3.09K
TXG:
9.39
DNTH:
$873.00K
TXG:
$638.78M
DNTH:
$873.00K
TXG:
$444.61M
DNTH:
-$187.38M
TXG:
-$5.89M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DNTH vs. TXG — Risk / Return Rank
DNTH
TXG
DNTH vs. TXG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Dianthus Therapeutics Inc. (DNTH) and 10x Genomics, Inc. (TXG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DNTH | TXG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.71 | ||
| Sortino ratioReturn per unit of downside risk | +1.63 | ||
| Omega ratioGain probability vs. loss probability | 1.69 | 1.43 | +0.26 |
| Calmar ratioReturn relative to maximum drawdown | 20.83 | 9.03 | +11.80 |
| Martin ratioReturn relative to average drawdown | 53.91 | 21.75 | +32.16 |
Loading charts...
Drawdowns
DNTH vs. TXG - Drawdown Comparison
The maximum DNTH drawdown since its inception was -53.48%, smaller than the maximum TXG drawdown of -96.47%. Use the drawdown chart below to compare losses from any high point for DNTH and TXG.
Loading charts...
Drawdown Indicators
| DNTH | TXG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.48% | -96.47% | +42.99% |
Max Drawdown (1Y)Largest decline over 1 year | -20.20% | -28.03% | +7.83% |
Max Drawdown (3Y)Largest decline over 3 years | — | -87.79% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -96.26% | — |
Current DrawdownCurrent decline from peak | -5.08% | -76.64% | +71.56% |
Average DrawdownAverage peak-to-trough decline | -17.26% | -60.10% | +42.84% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.79% | 11.62% | -3.83% |
Volatility
DNTH vs. TXG - Volatility Comparison
The current volatility for Dianthus Therapeutics Inc. (DNTH) is 18.40%, while 10x Genomics, Inc. (TXG) has a volatility of 22.62%. This indicates that DNTH experiences smaller price fluctuations and is considered to be less risky than TXG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DNTH | TXG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 18.40% | 22.62% | -4.22% |
Volatility (6M)Calculated over the trailing 6-month period | 45.89% | 50.59% | -4.70% |
Volatility (1Y)Calculated over the trailing 1-year period | 66.42% | 70.05% | -3.63% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 76.88% | 69.38% | +7.50% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 76.88% | 67.08% | +9.80% |
Dividends
DNTH vs. TXG - Dividend Comparison
Neither DNTH nor TXG has paid dividends to shareholders.
Financials
DNTH vs. TXG - Financials Comparison
This section allows you to compare key financial metrics between Dianthus Therapeutics Inc. and 10x Genomics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
DNTH and TXG have a correlation of 0.25, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TXG has higher volatility (22.62%) compared to DNTH (18.40%). In terms of maximum drawdown, DNTH dropped -53.48% vs TXG's -96.47%.
DNTH currently has the higher Sharpe Ratio (6.33 vs 3.62), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for DNTH and TXG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer